2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2021
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2020
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, Nemeroff CB, McDonald WM, Kalin NH. Hormonal Treatments for Major Depressive Disorder: State of the Art. American Journal Of Psychiatry 2020, 177: 686-705. PMID: 32456504, PMCID: PMC7841732, DOI: 10.1176/appi.ajp.2020.19080848.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorEndocrine GlandsHormonesHumansNeurosecretory SystemsTreatment OutcomeConceptsHypothalamic pituitary thyroidMajor depressive disorderMajor depressionDepressive disorderEffective treatmentGlucocorticoid receptor antagonist mifepristoneCorticotropin-releasing factor antagonistProgesterone derivative allopregnanoloneEstrogen replacement therapyTreatment of depressionNovel effective treatmentsCommon psychiatric disordersMore effective treatmentsNumber of hormonesWorld Health OrganizationTraditional antidepressantsAdjunctive treatmentAntagonist mifepristoneCNS effectsReplacement therapyDisease burdenGonadal axesPreclinical studiesFactor antagonistsHormonal treatment
2017
Ketamine as a Treatment for Adolescent Depression: A Case Report
Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. Ketamine as a Treatment for Adolescent Depression: A Case Report. Journal Of The American Academy Of Child & Adolescent Psychiatry 2017, 56: 352-354. PMID: 28335880, DOI: 10.1016/j.jaac.2017.01.006.Peer-Reviewed Case Reports and Technical Notes